Please upgrade your browser.
The international Phase 3 ADAPT study is expected to commence in mid-2012 under a revised Special Protocol Assessment (SPA) agreement with the FDA. This pivotal study will evaluate the addition of AGS-003 to standard therapy versus standard therapy alone.
The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients...
Within the NIH, several investigators have now begun to demonstrate the effectiveness of such precision attacks on various cancers, including lymphoma, kidney cancer, and prostate cancer, among others.
The 301 patients included in the analysis consisted of 133 women and 168 men who had a median age of 64 (range of 11 to 86). Their lung metastases arose from more than a dozen types of cancer. Colorectal cancer accounted for a third of cases, followed by renal cell carcinoma (12%), melanoma (7%), breast cancer (6%), soft-tissue sarcoma (6%), head and neck carcinoma (6%), and lung cancer (6%).
We present a 6th case of sarcomatoid chromophobe renal cell carcinoma, which had an osteosarcoma differentiation component. However, the correlation between the presence of heterologous elements and prognosis is unknown because of the rarity of this phenomenon.
There was no evidence of tumor recurrence in any of the patients.
Feeling frightened about one of your children having cancer is normal. The good news is that Wilms' tumour is curable in more than 9 out of 10 children (90%) diagnosed. [See: http://www.WilmsKids.org]
It's an extraordinary amount of power to give fifteen unelected individuals.
For the first time, the Kidney Cancer Association - M. D. Anderson National Patient & Survivor Meeting will be streamed live on YouTube.
Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist program, PRS-110, at the American Association for Cancer Research (AACR) Annual Meeting, further establishing the compound as a differentiated next generation therapeutic protein.
|NeonCRM by Neon One|